Brain Imaging Devices Market By Component (Imaging Equipment, Software, Services), By Technology (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Electroencephalography (EEG), Functional Near-Infrared Spectroscopy (fNIRS), Others), By Portability (Fixed Brain Imaging Systems, Portable Brain Imaging Devices, Wearable Imaging Devices), By Application (Neurological Disorders, Psychiatric Disorders, Brain Tumor Detection, Cognitive & Behavioral Research, Surgical Planning and Navigation, Drug Development and Clinical Trials, Others), and By End-user (Hospitals, Diagnostic Imaging Centers, Neurology & Psychiatry Clinics, Pharmaceutical Companies, Contract Research Organizations (CROs), Ambulatory Surgical Centers (ASCs), Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025–2035.

---

What trends will shape the Brain Imaging Devices Market in the coming years?

The Brain Imaging Devices Market accounted for USD 5.87 Billion in 2024 and USD 6.36 Billion in 2025 is expected to reach USD 14.11 Billion by 2035, growing at a CAGR of around 8.3% between 2025 and 2035. The Brain Imaging Devices Market will be influenced by increasing rates of neurological disorders, the greater need for early detection, and the embedding of AI to analyze images and diagnose specific patterns. PET/MRI systems and mobile or wearable concussion neuroimaging devices are becoming more common, particularly in research and long-distance care.

Further growth in the use of imaging in CNS drug development and clinical trials will also contribute to the CNS imaging market growth. In addition, functional imaging and real-time brain mapping development are allowing precision medicine and personal neurology. Such trends, together with the growing access in emerging markets, will change the market in the next few years.

What do industry experts say about the Brain Imaging Devices market trends?

“The future of neuroimaging lies in precision, portability, and AI-powered diagnostics. With hybrid systems and real-time brain mapping, we're entering a new era of personalized neuroscience.”

• Dr. Andreas Schneck, CEO, Positrigo AG.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Brain Imaging Devices market?

How is rising neurological disorder prevalence boosting global demand for brain imaging devices?

In the Brain Imaging Devices Market, the development of advanced imaging solutions is increasingly being achieved by the growing prevalence of neurological disorders that have gone global over the years. The extent of the problem is demonstrated by the research conducted in 2019 by the World Health Organization, suggesting that about 3.4 billion individuals, almost 43% of the world population, suffer the consequences of neurological disorders, which proves the significant importance of early and correct diagnosis.

Diseases like Alzheimer's, Parkinson's, epilepsy, and stroke are increasingly becoming common. This increased number is pushing the diagnostic centers and hospitals to use advanced imaging systems such as MRI, CT, PET, and EEG. Such tools have significant use in the detection of the neurologic abnormality, tracking the progress of the disease, and planning the treatment. These devices are getting more and more reliable due to improved accuracy and non-invasiveness, which makes them more widely used in the clinical setup. Also, rising awareness and screening programs at an early age will increase the scan volumes. Portable and wearable imaging systems are also experiencing tremendous demand because of the necessity of unremitted neurological monitoring. All these are rapidly boosting adoption and innovation in the brain imaging ecosystem.

Can AI-based imaging advancements enhance diagnostic accuracy and workflow efficiency in neurology applications?

In the Brain Imaging Devices Market, AI-based imaging developments are revolutionizing the neurology diagnostics approach since they improve the accuracy and make the workflow more efficient. Computer algorithms are now used to help in the early identification of neurological ailments by detecting minute patterns in brain scans that cannot be identified with the naked eye. The technologies save a lot of interpretation time and reduce errors, and standardize diagnostic outputs in diverse imaging systems.

Specifically, the AI instruments can be particularly effective during stroke evaluation, identifying brain tumors, and tracking the process of neurodegenerative disorders. They help clinicians improve their knowledge-based decisions at a faster rate, which is important in time-sensitive cases. Besides, the situation that AI allows using low-dose imaging without reducing the quality of a diagnosis enhances patient safety. As hospitals make more use of AI in MRI, CT, and EEG systems, throughput and resource optimization are improving in hospitals. AI tools used in neurology are also presented as effective according to regulatory acceptance, and they prove their medical utility. Since AI is every inch deep into imaging processes, it is transforming the way neurological issues are diagnosed and addressed worldwide.

Are the high costs of advanced imaging systems limiting adoption across lower-income healthcare settings?

In the Brain Imaging Devices Market, the fact that the advanced imaging systems cost a lot of money has actually become a restraining factor in terms of widespread usage in lower-income healthcare facilities. Photocopiers, MRIs, and PET scanners necessitate a high outlay of capital and continuous servicing and expertise, and thus are beyond the financial capability of most under-equipped hospitals and clinics. Such systems may equally demand other infrastructural facilities, like shielding rooms and large energy consumption, and increase operational expenses. Access is also limited by reimbursement policies and the funding of healthcare in most developing countries.

Consequently, this means that patients in low-income areas will experience late diagnosis, or they will have to travel far to come and have scans. The affordability gap is one of the contributors to health disparity, particularly in the management of complex neurological disorders. In some cases, manufacturers are presenting low-field or transportable imaging substitutes, although use is slacking since technology is always lacking, and there are hindrances due to regulations. These exigencies of cash and finance need to be addressed in order to ensure that there is a fair deal in healthcare delivery and even market penetration.

Will portable brain imaging devices revolutionize stroke detection in emergency and rural environments?

The portable brain imaging devices can be considered a game changer in terms of detecting strokes in emergency and rural areas in the Brain Imaging Devices Market. Recently, evidence indicated that in rural centers, stroke units only appear to treat about 3% of all stroke patients, in contrast to urban centers that treat 77% in hospitals.

Mobile stroke units that carry handheld CT or low-field MRI scanners can provide an image at the point of care and save the time it takes to diagnose and treat by orders of magnitude. Such systems also enable paramedics to scan and send the results using telemedicine, and be able to triage quickly and offer potential thrombolytic therapy. The portable devices also eliminate the use of a centralized hospital environment, reduce training costs, and delay the transfer of patients. They allow intervention at the golden hour, which is essential to the functional outcomes. These innovations might fill vital healthcare gaps and transform stroke care delivery in underserved groups as affordability and accessibility become increasingly available.

Can rising clinical trials expand the application of brain imaging in drug development?

In the Brain Imaging Devices Market, the increasing number of clinical trials is extending the application of brain imaging in drug development. U.S. government data show that imaging biomarkers, including MRI and PET, considered as surrogate endpoints, reduce trial size and accelerate effectiveness measurements. These imaging devices assist in monitoring anatomical and functional alterations in the brain, providing some insight into the response to treatment even before the patient experiences it.

When used in neurology trials, they can help select the participants, verify target engagement, and regulate safety, especially when it comes to diseases such as Alzheimer's and Parkinson's. Image endpoint standardization also improves between-study comparability. In the CNS drug studies, the imaging technologies are progressively becoming a crucial factor in proving biological impact as the technologies are increasingly becoming validated and integrated. It is an expansion that helps make drug development more efficient and objective, and adds value to investment in imaging.

What are the key market segments in the Brain Imaging Devices industry?

Based on the component, the Brain Imaging Devices Market is classified into imaging equipment, software, and services. The imaging equipment enjoys the largest market share, as there is a high demand for advanced MRI, CT, and PET equipment in hospitals and research institutes. Nevertheless, the software part of the market is growing quite fast, as the corrective tools involve the use of AI, machine learning, and 3D visualization, which helps to diagnose more correctly and effectively improve the speed of work. This segment is also extended by cloud-based platforms and real-time data analysis.

In the meantime, service segments such as installation activities, maintenance, and training also contribute to the establishment of operational continuity and compliance. Even the vendor-supplied support services are becoming more dependent in the case of neuroimaging technologies due to their increasing complexity. When combined with the other two working elements, all three elements are part and parcel to the enhancement and modernization of brain imaging capabilities in the world.

Based on the application, the Brain Imaging Devices Market is classified into neurological disorders, psychiatric disorders, brain tumor detection, cognitive & behavioral research, surgical planning and navigation, drug development and clinical trials, and others. The global burden of cases of neurological disorders, such as Alzheimer's, Parkinson's, epilepsy, and stroke, is increasing significantly. Depression and schizophrenia, the most common forms of psychiatric disorders, are also finding their way to image therapy as more people become aware and more funds are allocated to research.

The other important segment is brain tumor detection, which is nowadays easily detected by advanced MRI and PET technologies, thus allowing accurate localization and precise treatment planning. The clinical trials and drug development category is growing fast, with the pharma companies incorporating the use of imaging biomarkers to track the effects of the drugs. Neurosurgery. The field of neurosurgery is developing outcomes with real-time guidance by means of surgical planning and intraoperative imaging. Also, the application of cognitive and behavioral neuroscience is increasing in scholarly and research centers. The multiple applications contribute to the increase in demand for more specialized and high-resolution imaging solutions.

Which regions are leading the Brain Imaging Devices market, and why?

The North American Brain Imaging Devices Market is leading due to its well-developed healthcare system, high R&D competencies, and adoption of the latest imaging technologies. The highest percentage goes to the United States, driven by the fact that cases of neurological disorders and psychiatric disorders are on the rise, there is more spending on healthcare, and most importantly, there is a high penetration of market giants such as GE Healthcare and Siemens Healthineers.

Rampant application of the MRI, PET, and EEG machines in clinical and research studies drives the demands of the market. The region further enjoys a favorable reimbursement framework and immense government funding for brain research projects like the U.S. BRAIN Initiative. The increasing cooperation between the academic institutes and the pharma firms also speeds up the use of imaging in drug development. All these contribute to strengthening the position of North America as the leader in the world market of brain imaging devices.

The Asia Pacific Brain Imaging Devices Market is growing due to the enhanced level of awareness of neurological healthcare, growing accessibility of excellent diagnostic services, and swift expansion of healthcare infrastructure. The number of nations that have increased the demand for MRI, CT, and EEG systems has been observed to increase in countries such as China, India, Japan, and South Korea, where the aging population has been on the rise, and the rate of neurological diseases and disorders has also been on the rise.

Technology adoption is boosted by government efforts towards the modernization of medical processes, and an increase in investments by the government and the private sector. Expansion of medical tourism and more people entering clinical research will also lead to market growth. Also, a combination of local manufacturing and collaboration with international actors further boosts the affordability and accessibility of brain imaging technology in the region.

What does the competitive landscape of the Brain Imaging Devices market look like?

The most significant market players that govern the competitive environment of the brain imaging devices market include GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, and Fujifilm. These firms are constantly innovating in MRI, CT, PET, and hybrid imaging machines, especially in AI involvement, cloud-based platforms, and image-guided therapy systems. It has not been long since GE HealthCare partnered with UCSF in a bid to advance neuroimaging research in neurodegenerative diseases and oncology, which is another indicator of precision medicine. With the introduction of Biograph One PET/MR and helium-free MAGNETOM Flow MRI, Siemens Healthineers is the most recent company to evolve to sustainable and AI-driven technologies.

The investments that Philips is making include smart diagnostics and enterprise imaging in a bid to improve clinical efficiency. In the meantime, the new entrants like EMVision are gaining momentum regarding portable brain imaging devices, especially those used to diagnose stroke in pre-hospital environments. Precision Neuroscience and Paradromics are into high-resolution brain computers, the missing link between imaging and intervention on the neuron. Key competitive forces are increased collaborations, research investments, and digitalization strategies. Expansions within their regions and the customization of products to meet the needs of the high-income and emerging economies are also being experienced in the market.

Brain Imaging Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Brain Imaging Devices industry?

• In June 2025, Swiss startup Positrigo raised US$8.5 million to accelerate commercialization of its compact NeuroLF PET brain scanner, a space‑saving, chair‑based device cleared by the FDA for Alzheimer's, tumors, epilepsy, and Parkinson’s imaging
• In April 2025, Germany’s Forschungszentrum Jülich unveiled the BrainPET 7T insert for Siemens Magnetom Terra scanners, enabling ultra-high‑resolution simultaneous MRI/PET scans (≈1.6 mm resolution) in human trials this year, a major leap in hybrid neuroimaging technology

Report Coverage:

By Component

• Imaging Equipment
• Software
• Services

By Technology

• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT)
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Electroencephalography (EEG)
• Functional Near-Infrared Spectroscopy (fNIRS)
• Others

By Portability

• Fixed Brain Imaging Systems
• Portable Brain Imaging Devices
• Wearable Imaging Devices

By Application

• Neurological Disorders
• Psychiatric Disorders
• Brain Tumor Detection
• Cognitive & Behavioral Research
• Surgical Planning and Navigation
• Drug Development and Clinical Trials
• Others

By End-User

• Hospitals
• Diagnostic Imaging Centers
• Neurology & Psychiatry Clinics
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Ambulatory Surgical Centers (ASCs)
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Canon Medical Systems Corporation
• Fujifilm Holdings Corporation
• Hitachi Medical Systems Europe Holding AG
• Medtronic plc
• NeuroLogica Corporation
• Natus Medical Incorporated
• Bruker Corporation
• United Imaging Healthcare Co., Ltd.
• Positrigo AG
• EMVision Medical Devices Ltd.
• InfraScan Inc.
• Compumedics Limited

Frequently Asked Questions (FAQs)